A number of molecular therapeutic agents, derived from exploiting our knowledge of the oncogenic pathways that are frequently deregulated in cancer, are now entering clinical trials. One of these is the novel agent 17-allylamino-17-demethoxygeldanamycin that acts to inhibit the hsp90 molecular chaperone. Treatment of four human colon cancer cell lines with iso-eective concentrations of this agent resulted in depletion of c-raf-1 and akt and inhibition of signal transduction. We have used gene expression array analysis to identify genes responsive to treatment with this drug. The expression of hsp90 client protein genes was not aected, but hsc hsp70, hsp90b, keratin 8, keratin 18 and caveolin-1 were deregulated following treatment. These observations were consistent with inhibition of signal transduction and suggested a possible mechanism of resistance or recovery from 17-allylamino-17-demethoxygeldanamycin treatment. The results shed light on the molecular mode of action of the hsp90 inhibitors, and suggest possible molecular markers of drug action for use in hypothesis testing clinical trials. Oncogene (2000) 19, 4125 ± 4133.
Introduction
The search for innovative and eective cancer treatments has resulted in the focus of drug development shifting from cytotoxic compounds towards targeted therapeutics that act on speci®c molecular targets responsible for the malignant phenotype (Gelmon et al., 1999; Garrett and Workman, 1999) . One promising approach is the pharmacological targeting of signal transduction pathways that play a key role in oncogenic transformation and malignant progression (Gibbs and Oli, 1994; Hunter, 1997; Pawson and Saxton, 1999) . A number of agents that in¯uence signal transduction are currently under development, including small molecule inhibitors of key signalling molecules such as receptor tyrosine kinases, mek, phosphatidylinositol-3'-kinase and farnesyltransferase inhibitors that inhibit post-translational modi®cation of ras (Vlahos, 1995; Sebti and Hamilton, 1997; Strawn and Shawver, 1998; Sebolt-Leopold et al., 1999) .
The benzoquinone ansamycin antibiotics, such as geldanamycin and herbimycin, were identi®ed as agents which revert transformation by v-src and exhibit potent antitumour activity (Uehara et al., 1985 (Uehara et al., , 1986 Supko et al., 1995; Kelland et al., 1999) . Subsequent studies revealed that inhibition of c-src catalytic activity, the expected mechanism of action, was not responsible for antitumour activity (e.g. Brunton et al., 1998) . Anity binding experiments identi®ed the chaperone heat shock protein (hsp) 90 and its endoplasmic reticulum homologue, grp94, as the primary targets of geldanamycin (Whitesell et al., 1994; Chavany et al., 1996) . Signi®cantly, the family of hsp90 client proteins is limited to key signalling molecules such as receptor tyrosine kinases, c-raf-1, the src family kinases, cdk4 and the steroid hormone receptors that require hsp90 for correct conformation and stability (Miller et al., 1994; Murakumi, et al., 1994; Schulte et al., 1995; Stepanova et al., 1996; Whitesell and Cook, 1996; Schulte and Neckers, 1998; Buchner, 1999) . Thus geldanamycin interferes with signal transduction via an indirect route of signal complex destabilization that renders client proteins susceptible to degradation by the ubiquitination/proteasome pathway . Geldanamycin has limited clinical potential due to its liver toxicity (Supko et al., 1995) . However, the analogue 17-allylamino-17-demethoxygeldanamycin (17-AAG) has reduced liver toxicity but retains the potent antitumour activity of the parent compound (Schulte and Neckers, 1998; Schnur et al., 1995) . This derivative has very recently entered phase I clinical trial at our centre and in the USA under the auspices of the US National Cancer Institute and the UK Cancer Research Campaign.
One of the major challenges in the development of drugs with speci®c molecular targets is the con®rma-tion of the exact target mechanism of the agent in intact cells or tumours (Gelmon et al., 1999; Garrett and Workman, 1999) . A related objective is the characterization of molecular endpoints for action at the drug target. We reasoned that as modulation of signal transduction will elicit a wide variety of cellular responses including altered patterns of gene expression (Rollins and Stiles, 1989; Herschmann, 1991; Fambrough et al., 1999) , rational development of 17-AAG as a molecular therapeutic should include the identi®-cation of responsive genes with potential as pharmacodynamic markers. The regulation of transcription by signalling pathways is an extremely complex area depending on crosstalk between dierent pathways (Hunter, 1997). Therefore our approach required the application of high throughput mRNA analysis capable of parallel processing of large datasets. Consequently, to ensure the greatest chance of identifying 17-AAG responsive genes we decided to employ a gene array approach with the aim of examining global cellular gene expression following treatment of human colon adenocarcinoma cell lines with 17-AAG (Schena et al., 1996; DeRisi et al., 1996) ; Marton et al., 1998) . Not only would this approach maximize the opportunity of identifying a gene expression signature speci®c to 17-AAG action, but it would also provide clues to potential determinants of 17-AAG sensitivity and resistance. In this study we describe the identi®cation of genes responsive to 17-AAG in human colon cancer cell lines.
Results
Depletion of c-raf-1 following treatment with 17-AAG We initially measured c-raf-1 protein level to validate the action of 17-AAG in our own models. Human colon adenocarcinoma cells were exposed to 17-AAG for 24 h and then supplemented with drug-free medium. This allowed analysis of both response to and recovery from 17-AAG treatment. Figure 1 illustrates concentration-dependent depletion of c-raf-1 protein at 24 h following treatment of HT29 cells. The minimum concentration sucient to deplete each cell line of c-raf-1 at 24 h was approximately one to two times the IC 50 (HT29 ± 0.2 mM, HCT116 ± 0.9 mM, KM12 ± 0.8 mM, HCT15 ± 46 mM) for viability at 72 h and was used for all subsequent experiments. HT29 cells were the most sensitive to 17-AAG (0.5 mM), HCT116 and KM12 cells required 1 mM and HCT15 cells were the least sensitive, requiring 50 mM 17-AAG. These tumour lines also exhibited a range of timedependent responses following 17-AAG treatment. HCT116 cells recovered control levels of c-raf-1 protein at 48 h; in contrast, HT29 cells had not recovered craf-1 even at 72 h after treatment (Figure 1 ). KM12 and HCT15 cells had an intermediate response with evidence of limited c-raf-1 recovery at 72 h. Treatment with 17-AAG also resulted in the inhibition of signal transduction as evident by decreased erk-1/2 and c-akt phosphorylation (data not shown).
Array analysis of gene expression following 17-AAG treatment
We used a gene array of 4132 cDNA clones, corresponding to genes with a known identity, to analyse gene expression following 17-AAG treatment. In all cell lines the expression of the majority of genes remained unchanged following treatment (52.5-fold change; Figure 2 ). However, each cell line had a distinctive expression pro®le in response to 17-AAG treatment that to some extent re¯ected the pattern of craf-1 protein depletion and recovery described earlier.
Treatment of HCT116 cells with 17-AAG elicited surprisingly few changes in the gene expression pro®le at 24 h and these reverted to the control pattern at 48 h. Treatment of HT29 cells also resulted in .5-fold changes from control. Cells were treated with a single dose of 17-AAG sucient to deplete c-raf-1 at 24 h (HCT116 ± 1 mM, HT29 ± 0.5 mM, KM12 ± 1 mM, HCT15 ± 50 mM). PI=phosphorimaging units relatively few signi®cant alterations in the gene expression pro®le at 24 h, but unlike HCT116 at 48 h the gene expression pattern had changed signi®cantly from the controls at this later time. In contrast, treatment of both KM12 and HCT15 cells resulted in a considerably greater number of signi®cant alterations in gene expression after 24 h. However at 48 h the expression pro®le had reverted towards the control pattern of gene expression.
All of our expression data are available at http:// www.icr.ac.uk/cctherap. Cluster analysis of gene expression patterns was performed with the aim of identifying a node with genes whose expression was either increased or decreased in all four cell lines following treatment with 17-AAG. This analysis indicated a similarity between HCT116 and HT29 cells which were signi®cantly dierent from KM12 and HCT15 cells. Figure 3 illustrates the hierarchical relationship of the expression pro®les of the control and treated cell lines. Although we were able to identify gene clusters within the data, we were unable to identify a speci®c set of genes that were regulated by 17-AAG in all the four tumour cell lines studied here. This was despite the fact that iso-eective doses of 17-AAG depleted c-raf-1 to the same extent in all four lines, but may be related to our observation that the recovery kinetics diered markedly across the cell line panel. Therefore we examined expression of particular individual genes that might in¯uence this response and also the expression of several interesting genes that were dierentially regulated by 17-AAG.
Expression of hsp90 clients and genes that influence the cellular pharmacology of 17-AAG
The dierential response to 17-AAG could reside in the ability of various cell lines to respond by increasing the expression of genes encoding critical hsp90 client proteins that are depleted by drug treatment (Buchner, 1999) . However, with the exception of caesin kinase ± Figure 3 Hierarchical clustering of control and 17-AAG treated cells. Gene expression data were analysed using the clustering algorithm of Eisen et al. (1998) 1g expression, there were no signi®cant or consistent alterations in the expression pattern of c-raf-1 or other genes encoding hsp90 client proteins (Table 1) . A potential complication, which could give rise tò o-target' gene expression changes, was the metabolic reduction of the quinone ring of 17-AAG (Kelland et al., 1999) . This might be a potential source of DNA damaging reactive oxygen species that would result in p53 induction. However, this was unlikely to be a signi®cant factor in the response of the only p53 wildtype cell line studied here, HCT116, as there was no evidence for transactivation of p53-regulated genes such as mdm-2, pcna, or pig-3, -7, -8, -10, -11 or -12 (Table 2) .
Eux or metabolism of 17-AAG might also contribute to a dierential response to 17-AAG. Sensitivity to geldanamycin has been associated with p-glycoprotein (mdr1) and multidrug resistance protein (mrp) status (Kelland et al., 1999) . HCT116 did not exhibit signi®cantly elevated or inducible expression of these genes or other known homologues responsible for drug eux (Table 1) . HCT15, the only line with an mdr-phenotype, demonstrated the highest levels of mdr1 and mrp1 expression, an observation also consistent with the high concentration of 17-AAG required to aect this cell line (Kelland et al., 1999) . The formation of the major 17-AAG degradation product, 17-amino-17-demethoxygeldanmycin (17-AG), is catalyzed by the cytochrome p450 cyp3A4 isoform (Egorin et al., 1998) . We were unable to measure cyp3A4 using the array, but this activity was unlikely to be a factor since 17-AG is equally eective as 17-AAG in all the cell lines tested (Kelland et al., 1999) .
17-AG may be metabolized by microsomal epoxide hydrolase, but expression of this gene was relatively similar across the cell line panel and was not elevated or induced in HCT116 cells (Table 1; Egorin et al., 1999) . Levels of the quinone metabolizing enzyme DTdiaphorase (NQO1) have been signi®cantly correlated with sensitivity to 17-AAG (Kelland et al., 1999) . NQO1 expression was low in KM12 cells and was reduced following treatment of HCT15 cells; however, there were no signi®cant dierences between HCT116 and HT29 cells. Thus the rapid recovery of HCT116 cells could not be attributed to known genes involved in 17-AAG eux or metabolism.
Genes regulated by 17-AAG treatment
Inspection of the gene expression data allowed us to identify some interesting and potentially signi®cant changes in expression of individual genes. Of particular interest were the genes encoding members of the hsp90 Figure 4 Gene array analysis of gene expression (arbitrary phosphorimaging units) and pseudo-coloured data for the expression of genes signi®cantly altered following 17-AAG treatment of colon tumour cells (HCT116 ± 1 mM, HT29 ± 0.5 mM, KM12 ± 1 mM, HCT15 ± 50 mM). Each pseudo-coloured spot is a ratio of expression in control cells compared to 17-AAG treated cells (green=increased by 17-AAG treatment, yellow=un-changed, red=decreased by 17-AAG treatment) Figure 5 The top panel shows phosphorimaging data of caveolin-1 gene expression in all colon cancer lines after 24 h treatment with 17-AAG (HCT116 ± 1 mM, HT29 ± 0.5 mM, KM12 ± 1 mM, HCT15 ± 50 mM). The bottom panel shows Western blotting analysis of caveolin-1 protein expression in HCT116 cells after 24 h treatment with 1 mM 17-AAG and hsp70 molecular chaperone genes. Consistent with other array studies in dierent tumour cell types (Fambrough et al., 1999; Amundson et al., 1999) , constitutive expression of the hsp90b isoform, but not the hsp90a isoform, was detected in all four tumour lines. At 24 h, treatment of HCT116 cells resulted in signi®cantly increased expression of heat shock cognate (hsc) 70 and the 17-AAG molecular target hsp90b. Hsc70 was also induced following treatment of HCT15 cells, while hsp70 and hsp90b were both induced following treatment of KM12 cells. In contrast, HT29 cells had signi®cantly elevated hsc70 at 48 h, but barely detectable levels of hsp90b that were not induced by 17-AAG (Figure 4 and Table 3 ).
Expression of genes such as c-fos and cyclin D1 are regulated by a number of signalling pathways (Price et al., 1996; Lavoie et al., 1996) . Considering the range of inhibitory eects of 17-AAG on signal transduction proteins, we hypothesized that the expression of genes such as c-fos and cyclin D1 should be inhibited by 17-AAG treatment; however this was not the case (Table  2) . Keratin 8 and 18 gene expression is regulated through ras signalling and both isoforms are expressed in epithelial tissue and tumours derived from such tissue (Oshima et al., 1996) . Interestingly, in the present study expression of these genes was signi®cantly repressed following 17-AAG treatment of KM12, HT29 and HCT15, but was signi®cantly induced after 24 h treatment of HCT116 cells (Figure 4 and Table 3) . Also of interest, we were able to detect increased expression of caveolin-1, a gene whose expression is suppressed by an active raf/mek/erk pathway (Engelman et al., 1998) . Caveolin-1 expression was restricted to HCT116 cells where the increase was detected at both the RNA and protein levels ( Figure 5) .
To con®rm the changes in hsp expression detected by array analysis, we measured protein levels of hsc/hsp70 and hsp90b following 17-AAG treatment of HCT116 and HT29 cells (Figure 6 ). Hsp90b and total hsc/hsp70 were both increased following 17-AAG treatment of HCT116 cells. Similarly, treatment of HT29 cells also induced total hsc/hsp70, but in contrast to HCT116 cells, hsp90b levels were depleted by 17-AAG. The eects of 17-AAG on hsp90b were also maintained up to 72 h after 17-AAG treatment.
Induction of hsc/hsp70 and hsp90b is not a non-specific stress response
It was possible that the induction of hsc/hsp70 and hsp90 was a consequence of stress induced by treatment with 17-AAG. Paclitaxel is a cytotoxic agent that blocks mitosis by binding and stabilizing microtubules, but has also been reported to bind hsp90 (Byrd et al., 1999) . Therefore we examined the speci®city of hsp induction by treating HCT116 and HT29 cells with cytotoxic doses of paclitaxel. The expression of c-raf-1 and hsp90b were measured by Western blotting. HCT116 cells had considerably higher constitutive levels of hsp90b compared to HT29 (Figure 7 ) and paclitaxel treatment failed to signi®cantly alter c-raf-1 or hsp90b expression.
Ex vivo treatment of peripheral blood lymphocytes
In addition to understanding molecular mechanisms of action, an additional advantage of gene expression analysis is the identi®cation of markers that can be used to determine whether the molecular target has been modulated during early clinical trials. We tested the clinical potential of our observations using an ex vivo model of freshly isolated human peripheral blood lymphocytes treated with a pharmacologically relevant concentration of 17-AAG (1 mM). 17-AAG activity was con®rmed by the depletion of c-raf-1 and lck, a src family haemopoietic lineage-speci®c hsp90 client protein (data not shown). Keratin 8 and 18 expression were not analysed as their expression is speci®c to epithelial tissue, and we could not detect expression of caveolin-1 or hsp90b in control lymphocytes (data not shown). However, we could clearly detect the induction of hsp70 following 17-AAG treatment (Figure 7 ).
Discussion
Gene expression pro®ling is a powerful technique to investigate the molecular mechanisms of action of the new generation of molecular therapeutics that have been developed to take advantage of our knowledge of the deregulated signal transduction pathways responsible for driving the tumour phenotype. In the present paper we have used this technology to investigate the molecular eects of the signal transduction inhibitor 17-AAG on human colon cancer cells. This agent is the ®rst inhibitor of the hsp90 molecular chaperone to enter clinical trials, which are currently underway in our centre and the USA under the auspices of the US National Cancer Institute and the UK Cancer Research Campaign. Since hsp90 inhibition leads to depletion of oncogenic kinases, including c-raf-1 and cakt, and hence inhibition of the ras/raf/mek/erk and phosphatidylinositol-3'-kinase pathways, we expected to see a considerable range of gene expression changes. Therefore, global analysis using gene array technology was particularly appropriate. The primary objective was to identify the genes whose expression was modulated in response to 17-AAG treatment. Two bene®ts were anticipated from this knowledge. The ®rst is to gain a better understanding of the molecular mechansim of action of the drug in tumour cells. The second is to provide molecular markers of 17-AAG action that could be used to determine whether the drug was exhibiting the desired eect in treated patients. Although gene arrays have been widely used to pro®le gene expression in untreated tumours and in tumour cell lines in response to genotoxic damage, to our knowledge there has only been a single publication dealing with the response of tumour cells to drug treatment (DeRisi et al., 1996; Khan et al., 1998; Amundson et al., 1999; Hilsenbeck et al., 1999) .
Despite using sucient drug to deplete c-raf-1 in all the tumour lines studied, 17-AAG failed to induce certain anticipated changes in gene expression and in fact there were few if any consistent signi®cant changes across the cell line panel. In the cell lines we have studied, 17-AAG inhibits ras/raf/mek and phosphatidylinositol-3'-kinase signalling pathways and one might predict that this would lead to reduced expression of genes such as c-fos and cyclin D1 (Price et al., 1996; Lavioe et al., 1996) . However, no changes were seen for these genes. Interestingly, recent studies have noted that c-fos expression is not reduced by geldanamycin treatment of HT29 cells and treatment of cells with herbimycin, a benzoquinone ansamycin similar to geldanamycin, does not decrease cyclin D1 mRNA levels, but regulates cyclin D1 expression at the posttranscriptional level (Muise-Helmericks et al., 1998; Vasilevskaya and O'Dwyer, 1999) .
One change that did appear to be consistent across all our tumour lines was increased expression of hsc/ hsp70. Induction of hsp70 by 17-AAG has been reported in an additional colon adenocarcinoma cell line (Kelland et al., 1999) and following geldanamycin or herbimycin treatment of src-transformed NIH3T3 cells (Murakami et al., 1991; Whitesell et al., 1994) . This suggests that induction of hsc/hsp70 could be one suitable molecular marker for 17-AAG action or inhibition of hsp90. Another signi®cant change induced by 17-AAG was expression of one isoform of the molecular target of 17-AAG, that is hsp90b. In two cell lines, HCT116 and KM12, 17-AAG induced hsp90b expression, in contrast hsp90b was barely detectable in HT29 cells and was depleted following 17-AAG treatment. These changes are not speci®c to colon adenocarcinomas as we have detected a similar range of responses, at the protein level, following in vitro and in vivo treatment of ovarian adenocarcinoma cells (unpublished observations).
Also of note, we detected reduced keratin 8/18 expression by microarray following 17-AAG treatment of HT29, KM12 and HCT15 colorectal adenocarcinoma cells. In contrast, there was an increase in keratin 8/ 18 expression in HCT116 cells, although these observations require con®rmation by Northern or Western blotting. The developmental regulation of these two genes is complex; however, their expression in tumour cells is driven through ras signalling by ap-1 and ets transcription factors (Oshima et al., 1996) . An active ras/raf/mek pathway represses caveolin-1 expression (Engelman et al., 1998) . In the present study, only one cell line, HCT116, expressed detectable caveolin-1 mRNA. We have however, detected caveolin expression in approximately 50% of a larger panel of 30 tumour cell lines (data not shown). Interestingly, treatment with 17-AAG induced caveolin-1 expression at both the RNA and protein level. These observations suggest inhibition of the ras/raf/mek/erk signalling pathway, consistent with depletion of c-raf-1 and inhibition of erk-1/2 phosphorylation.
The mechanisms involved in the gene expression changes induced by 17-AAG are obviously of interest. Hsp70 and hsp90 expression are primarily regulated by heat shock factor 1 that in the absence of stress is maintained as an inert monomer by complexing with hsp90 (Zou et al., 1996) . Reduced hsp90 results in activation of this factor, an eect mimicked by geldanamycin inhibition of hsp90 (Zou et al., 1996) . In addition, hsc70 and hsp90b expression can be regulated by mitogen stimulation (Hansen et al., 1991) . One might speculate that the explanation for depletion of hsp90b in HT29 cells is that, like its clients, hsp90b is degraded by the proteasome, although degradation by other proteases could also be responsible. However, if this were a general mechanism, depletion of hsp90b would be expected in all the cell lines used in this study. HCT116 and KM12 cells respond to 17-AAG by inducing hsp90b expression, therefore the inability to increase hsp90b expression may also be a factor in hsp90b depletion in HT29 cells. Future studies will require promoter footprinting, gel shift analysis and reporter gene studies in control and 17-AAG treated cells to de®ne whether the dierent hsp, keratin 8/18 and caveolin-1 expression patterns in the cells studied here are due to regulation by cis and/or trans factors.
The relatively poor constitutive expression of hsp90b and its depletion following treatment of HT29 cells may explain the inability of this cell line to recover c-raf-1 protein expression following 17-AAG treatment. In contrast, the induction of the hsp90b target in HCT116 cells may be part of a recovery mechanism in these cells. An additional contributory factor to the rapid recovery of HCT116 could be the induction of caveolin-1 or keratin 8 and 18. Caveolin-1 binds and regulates the activity of a number of signalling molecules including src and ras (Li et al., 1996) . Keratin 8/18 form intermediate ®laments that are required by hsp90 to ful®l its full chaperone activity (Galigniana et al., 1998) . It is tempting to speculate that changes in caveolin-1 and keratin genes, in addition to hsp90b, may contribute to cellular recovery from 17-AAG treatment. For example these changes may explain the dierence between the rapid recovery of HCT116 cells which show induced hsp90b, caveolin-1 and keratin-8 and -18 expression, and the slower partial recovery of KM12 cells which induce hsp90b expression, but have undetectable caveolin-1 expression and exhibit repressed keratin-8 and -18 expression following 17-AAG treatment. Gene transfer experiments with the HT29 cell model will be used to explore the contribution of increased hsp90, caveolin-1 and keratin 8 and 18 to recovery from 17-AAG treatment. Understanding the molecular basis of recovery from 17-AAG treatment may have clinical signi®cance since it is likely to in¯uence the way this molecular therapeutic is used in cancer patients, particularly in terms of frequency of dosing.
Of the ®ve potential molecular markers of 17-AAG identi®ed by our gene array analysis of colon tumour cells, only hsp70 was expressed and induced following ex vivo treatment of human peripheral blood lymphocytes. This illustrates the requirement for array studies with the appropriate surrogate tissue of choice. Tumour biopsies provide the ideal material in which to determine the molecular response, and the various genes identi®ed here, together with client proteins, are candidates for analysis in clinical studies. However, for clinical and logistic reasons, tumour biopsies can only be obtained in a fraction of patients in clinical trials. An alternative is to analyse surrogate tissue such as lymphocytes and also buccal mucosa which may express keratin-8, -18, hsp90b and caveolin-1. As part of our own phase I evaluation of 17-AAG, in addition to monitoring hsp90 clients such as c-raf-1, both gene and protein expression of the 17-AAG responsive genes we have identi®ed here will be analysed in peripheral blood lymphocytes and where possible tumour biopsies. In parallel, further gene array analysis of these samples will also be used to identify additional markers of 17-AAG action in the clinical setting.
Although extensive, our array studies presented here have looked at only 3 ± 4% of the 100 000-plus genes that are likely to be encoded by the human genome. Nevertheless this analysis has already revealed a number of interesting and potentially important changes in gene expression. These changes may be important in understanding the molecular mode of action of 17-AAG and may shed light on factors contributing to drug sensitivity and recovery. The gene array analysis has generated a number of potential genes that may regulate therapeutic response, and these can now be evaluated in hypothesis-driven gene transfer/knock-out studies. In addition, the identi®ca-tion of genes whose expression is altered by 17-AAG may allow the development of molecular markers of drug action that can be used to test whether this particularly interesting experimental drug is acting by the desired mechanism of hsp90 inhibition and signal transduction inhibition in patients.
Materials and methods

Reagents and drugs
17-AAG was kindly supplied via Dr E Sausville (NCI, USA) and paclitaxel was obtained from Sigma (UK).
Cell lines and treatment
Colon adenocarcinoma cell lines (HCT116, HT29, KM12 and HCT15) were obtained from commercial cell culture collections (ATCC, USA) and were cultured in Dulbecco's minimal essential medium without sodium pyruvate (Life Technologies, UK) supplemented with 10% foetal calf serum (PAA laboratories, UK), 16non-essential amino acids (Life Technologies, UK), 2 mM L-glutamine, 50 U/ml penicillin and 50 mg/ml streptomycin in a 5% CO 2 atmosphere. All cell lines were PCR tested free of Mycoplasma contamination. Cells in mid-log phase of growth were exposed to 17-AAG for 24 h. The cells were then washed and supplemented with fresh drug-free media and harvested for molecular analysis immediately or at 48 and 72 h. Peripheral blood lymphocytes were collected, isolated by centrifugation through Ficollpaque, and maintained as a stationary suspension in RPMI1640 supplemented with 2 mM L-glutamine and 20% foetal calf serum. Cells were treated with 1 mM 17-AAG and protein isolated over a 24 h period.
Analysis of RNA
Cells (10 7 cells/ml) were lysed in denaturing buer (2.7 M guanidium thiocyanate, 1.3 M ammonium thiocyanate, 100 mM NaOAc pH 4.0) and extracted twice with saturated phenol (0.61 g/ml phenol, 16% v/v glycerol, 100 mM NaOAc pH 4.0) and chloroform. Poly(A) + mRNA was prepared from total RNA using oligo(dT) cellulose (Micro-FastTrack TM 2.0, Invitrogen, USA). Radiolabelled single-strand cDNA was prepared from 50 ± 100 ng of Poly(A) + mRNA by incubation for 2 h at 428C with 10 U/ml Superscript TM II reverse transcriptase (Life Technologies), 1 mM dATP, 1 mM dTTP, 1 mM dGTP and 100 mCi [a 33 P]dCTP (3000 Ci/mmol; ICN Pharmaceuticals, USA). Unincorporated nucleotides were removed using Probe-Quant TM sephadex G50 microcolumns (Amersham Pharmacia Biotech, UK). Radiolabelled cDNA was hybridized to commercially available gene arrays carrying 4132 I.M.A.G.E/LLNL cDNA clones spotted on nylon membranes (Sgroi et al., 1999; GF211, Research Genetics, USA) . Hybridization was performed in MicroHyb TM (Research Genetics, USA) containing 1 mg/ml denatured human Cot-1 DNA (Life Technologies, UK) and 1 mg/ ml poly(dA) overnight at 428C in a hybridization oven (Hybaid, UK). Membranes were washed twice for 30 min in 26SSC, 1% SDS at 508C and once at room temperature in 0.56SSC/1% SDS. Hybridization signals were detected by phosphorimaging (Storm Phosphorimager, Molecular Dynamics, USA) and an intensity output produced using Pathways TM 2.01 image analysis software (Research Genetics, USA). Signal intensity was normalized using a set of 88 control genes that have been reported to have consistent expression levels across a number of cell lines and conditions (Amundson et al., 1999; Hilsenbeck et al., 1999) . All array experiments were performed in duplicate. A +2.5-fold change in gene expression was considered signi®cant; this was the minimum level of change that could be reliably and reproducibly detected by RNase protection analysis and is consistent with cut-o levels described in the literature (Schena et al., 1996; Amundson et al., 1999; Hilsenbeck et al., 1999) . Cluster analysis was performed using the method of Eisen et al. (1998) . Several alterations in gene expression detected by array analysis were subsequently con®rmed by protein analysis.
Analysis of protein
Cells were washed twice with PBS and resuspended in lysis buer (150 mM NaCl, 50 mM tris.HCl pH 8.0, 0.2% w/v SDS, 0.2% v/v NP40, 1% v/v glycerol, 1 mM EDTA, 0.5 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 100 mM NaF and 16protease inhibitors (Complete TM , Mini-Tabs; Boehringer Mannheim, Germany)). Following lysis an equal volume of 80 mM tris.HCl, 6 mM MgCl 2 solution was added to the lysate, an aliquot was removed for protein estimation and the remainder was stored at 7708C. Protein concentration was determined by Lowry assay (BioRad, UK). Equal amounts of protein (maximum 100 mg/lane) and Rainbow TM molecular weight markers (Amersham Pharmacia Biotech, UK) were separated by electrophoresis through polyacrylamide gels as described by Laemmli (1970) and electro-transferred to Hybond-C nitrocellulose (Amersham Pharmacia Biotech, UK) by the method of Towbin et al. (1979) . Immunoblots were blocked with 5% non-fat milk in TBST (10 mM tris.HCl pH 7.6, 142 mM NaCl, 0.1% Tween-20) and then incubated with 0.4 mg/ml anti-c-Raf-1 rabbit polyclonal antibody (Santa Cruz, USA), 0.05 mg/ml anti-mouse hsp84 rabbit polyclonal antibody (equivalent to human hsp90b; Aniti Laboratories, USA), 1.1 mg/ml anti-hsc/hsp70 mouse monoclonal antibody (Stressgen Biotech. Corp., USA), 1.2 mg/ml anti-hsp70 mouse monoclonal antibody (Stressgen Biotech. Corp., USA), 0.8 mg/ml caveolin-1 rabbit polyclonal antibody (Santa Cruz, USA) or 20 mg/ml anti-GAPDH mouse monoclonal antibody (Chemicon, USA). Speci®c antigen-antibody interaction was detected with horse-radish peroxidase-conjugated goat antimouse or anti-rabbit immunoglobulin G using enhanced chemiluminescence Western blotting detection reagents (Amersham Pharmacia Biotech, UK).
Abbreviations 17-AAG, 17-allylamino-17-demethoxygeldanamycin; 17-AG, 17-amino-17-demethoxygeldanmycin; hsp, heat shock protein; hsc, heat shock cognate.
